- A systematic review and meta-analysis suggest that supplementation with omega-3 polyunsaturated fatty acids (PUFA) is associated with beneficial clinical effects for patients with psoriasis.
Why this matters
- Individual studies have yielded inconsistent results.
- Omega-3 PUFA supplementation was associated with reduced Psoriasis Area and Severity Index (PASI) score compared with control (−1.58; P<.00001 standardized mean difference ci to>
- Omega-3 PUFA supplementation was also associated with reduced erythema (−1.66 units; P=.0001; SMD, −1.55; 95% CI, −2.47 to −0.62) and scaling (weighted mean difference, −0.69; P=.02; SMD, −2.06; 95% CI, −3.66 to −0.46) compared with control.
- Omega-3 PUFA supplementation was not significantly associated with improvements in percentage of total body surface area affected, desquamation, or infiltration (P>.05 for all).
- Significant improvements in erythema, itching, and scaling were observed in the trials that used a higher dosage of omega-3 PUFA supplementation (≥1800 mg/day).
- 560 patients with psoriasis from 10 studies were included in the meta-analysis.
- Funding: None disclosed.
- Small sample sizes in included trials.
- Heterogeneity between included studies.